biostudies-literatureUnknown15Wang X<h4>Objectives</h4>To assess the effectiveness of various atropine concentrations in managing myopia among children in East, South, and Southeast Asia, and to determine the most effective concentration.<h4>Methods</h4>A systematic literature review was conducted using PubMed, Web of Science, Cochrane Library, and EMBASE. The search was limited to articles published up to 1 June 2024, and included studies in Chinese or English. Two researchers independently screened the literature, extracted relevant data, and assessed the data quality using the Revised Cochrane risk-of-bias 2 (RoB2) tool. A network meta-analysis was performed using Stata 14.2 software to compare the efficacy of different atropine concentrations in delaying myopia progression, measured by changes in refraction and axial length.<h4>Results</h4>The analysis included 39 studies with 7,712 participants, examining 10 atropine concentrations ranging from 0.005% to 1%. Forest plots indicated that five concentrations (0.01%, 0.02%, 0.025%, 0.05%, and 1%) were more effective than a placebo in controlling myopia progression. The cumulative ordination plot indicated that 0.05% atropine most effectively delayed refraction change, which the mean change per year was 0.62D, while 1% was superior in slowing axial length progression, which the mean change per year was -0.43 mm. Considering both measures, 1% atropine showed the highest efficacy which the mean changes per year were 0.56D in spherical equivalent refraction and -0.43 mm in axial length, followed by 0.05% and 0.125% atropine.<h4>Conclusion</h4>While 1% atropine demonstrated the highest efficacy in myopia control among East, South and Southeast Asian children, its use is not recommended due to increased adverse effects and a rapid rebound in myopia after cessation. Considering both efficacy and safety, 0.05% atropine is suggested as the optimal concentration for myopia management in this population.Frontiers in pharmacology1503536https://www.ebi.ac.uk/biostudies/studies/S-EPMC11683068biostudies-literatureEffectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.PMC11683068Yang WGan JWang XZhang LWang YfalseEffectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.<h4>Objectives</h4>To assess the effectiveness of various atropine concentrations in managing myopia among children in East, South, and Southeast Asia, and to determine the most effective concentration.<h4>Methods</h4>A systematic literature review was conducted using PubMed, Web of Science, Cochrane Library, and EMBASE. The search was limited to articles published up to 1 June 2024, and included studies in Chinese or English. Two researchers independently screened the literature, extracted relevant data, and assessed the data quality using the Revised Cochrane risk-of-bias 2 (RoB2) tool. A network meta-analysis was performed using Stata 14.2 software to compare the efficacy of different atropine concentrations in delaying myopia progression, measured by changes in refraction and axial length.<h4>Results</h4>The analysis included 39 studies with 7,712 participants, examining 10 atropine concentrations ranging from 0.005% to 1%. Forest plots indicated that five concentrations (0.01%, 0.02%, 0.025%, 0.05%, and 1%) were more effective than a placebo in controlling myopia progression. The cumulative ordination plot indicated that 0.05% atropine most effectively delayed refraction change, which the mean change per year was 0.62D, while 1% was superior in slowing axial length progression, which the mean change per year was -0.43 mm. Considering both measures, 1% atropine showed the highest efficacy which the mean changes per year were 0.56D in spherical equivalent refraction and -0.43 mm in axial length, followed by 0.05% and 0.125% atropine.<h4>Conclusion</h4>While 1% atropine demonstrated the highest efficacy in myopia control among East, South and Southeast Asian children, its use is not recommended due to increased adverse effects and a rapid rebound in myopia after cessation. Considering both efficacy and safety, 0.05% atropine is suggested as the optimal concentration for myopia management in this population.2024-01-01T00:00:00Z20242025-04-04T08:11:41.703Z2025-04-04T08:11:41.703ZS-EPMC116830683973707310.3389/fphar.2024.1503536